Dudley Capital Management LLC Cuts Position in Pfizer Inc. (NYSE:PFE)

Dudley Capital Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 1.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,531 shares of the biopharmaceutical company’s stock after selling 637 shares during the period. Dudley Capital Management LLC’s holdings in Pfizer were worth $1,473,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of PFE. Nordea Investment Management AB lifted its position in Pfizer by 36.1% during the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock valued at $108,002,000 after purchasing an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI raised its position in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after buying an additional 159,984 shares in the last quarter. NFJ Investment Group LLC lifted its holdings in shares of Pfizer by 12.8% in the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company’s stock valued at $11,129,000 after acquiring an additional 43,719 shares during the last quarter. Daiwa Securities Group Inc. grew its position in Pfizer by 25.9% in the third quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company’s stock worth $23,283,000 after acquiring an additional 165,611 shares in the last quarter. Finally, Copley Financial Group Inc. bought a new stake in Pfizer during the third quarter worth approximately $577,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PFE shares. UBS Group lowered their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Price Performance

Shares of PFE stock opened at $26.13 on Tuesday. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $148.21 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 0.64 and a beta of 0.61. The stock’s 50-day simple moving average is $26.15 and its 200-day simple moving average is $27.02.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.